Results of small study show ALK inhibitor crizotinib had robust and sustained activity in patients with relapsed ALCL.
Home / Resource Library / Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children’s Oncology Group Study